Table 4.
Groups | Liver function markers | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
ALT (U/L) | AST (U/L) | ALP (U/L) | LDH (U/L) | GGT (U/L) | Total bilirubin (mg/dL) | Total protein (g/L) |
Albumin (g/L) | Globulin (g/L) | A/G ratio | |
Normal Control | 44.67 ± 2.87# | 81.67 ± 2.87 | 231.67 ± 9.53# | 104.33 ± 18.37# | 1.33 ± 0.47# | 0.10 ± 0.01# | 59.73 ± 1.52 | 11.53 ± 0.59 | 48.2 ± 1.60 | 0.23 ± 0.01 |
Diabetic Control | 82.67 ± 16.21 | 86.00 ± 8.64 | 973.67 ± 31.71 | 290.00 ± 28.85 | 6.33 ± 0.47 | 0.23 ± 0.04 | 65.50 ± 4.54 | 10.46 ± 1.65 | 55.03 ± 5.10 | 0.19 ± 0.04 |
Diabetic + Glibenclamide | 42.67 ± 3.40∗ | 68.00 ± 5.34∗ | 608.67 ± 7.59∗ | 163.67 ± 3.68∗ | 3.67 ± 0.47∗ | 0.10 ± 0.04∗ | 62.60 ± 1.31 | 11.53 ± 0.60 | 51.06 ± 0.88 | 0.22 ± 0.01 |
Diabetic + GP (250 mg/kg) | 55.25 ± 5.53∗ | 77.25 ± 4.81 | 625.00 ± 46.18∗ | 135.50 ± 32.53∗ | 5.00 ± 1.22 | 0.18 ± 0.04 | 62.63 ± 4.69 | 10.55 ± 0.45 | 52.07 ± 4.40 | 0.20 ± 0.01 |
Diabetic + GP (500 mg/kg) | 47.33 ± 3.29∗ | 64.33 ± 1.69∗ | 572.00 ± 35.44∗ | 142.00 ± 23.37∗ | 4.67 ± 1.24 | 0.10 ± 0.01∗ | 60.67 ± 2.11 | 9.33 ± 0.74 | 51.33 ± 2.05 | 0.18 ± 0.01 |
Diabetic + GP (1000 mg/kg) | 44.50 ± 3.35∗ | 72.50 ± 2.50∗ | 397.75 ± 42.41∗ | 110.75 ± 15.36∗ | 4.00 ± 0.71∗ | 0.08 ± 0.04∗ | 63.00 ± 2.14 | 12.57 ± 0.54 | 50.42 ± 2.51 | 0.25 ± 0.02∗ |
Data are represented as the mean ± SD (n = 8). ∗ denotes a significant difference (p < 0.05) between the treatment groups and the diabetic control group; # denotes a significant difference (p < 0.05) when the normal control group was compared to the diabetic control group. The comparisons were made by one-way ANOVA followed by Dunnett's multiple comparison test.